- Home
- UAL vs ILMN Comparison
UAL vs ILMN Comparison
Compare UAL & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UAL | ILMN |
|---|---|---|
| Founded | 1934 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 18.9B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | UAL | ILMN |
|---|---|---|
| Price | $112.82 | $130.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 15 | 16 |
| Target Price | ★ $129.50 | $116.19 |
| AVG Volume (30 Days) | ★ 5.9M | 1.7M |
| Earning Date | 01-20-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.30 | N/A |
| EPS | ★ 9.99 | 4.46 |
| Revenue | ★ $58,369,000,000.00 | $4,288,000,000.00 |
| Revenue This Year | $4.70 | N/A |
| Revenue Next Year | $7.65 | $2.08 |
| P/E Ratio | ★ $11.30 | $29.26 |
| Revenue Growth | ★ 4.24 | N/A |
| 52 Week Low | $52.00 | $68.70 |
| 52 Week High | $116.00 | $153.06 |
Technical Indicators
Market Signals| Indicator | UAL | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 65.67 | 59.09 |
| Support Level | $106.28 | $129.29 |
| Resistance Level | $114.83 | $137.09 |
| Average True Range (ATR) | 3.38 | 3.60 |
| MACD | 0.73 | -0.87 |
| Stochastic Oscillator | 86.56 | 53.88 |
Price Performance
Historical ComparisonAbout UAL United Airlines Holdings Inc.
Chicago-based United Airlines is a major US network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel, especially across the Pacific, than its large US peers.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.